J&J keeps cash flowing on blockbuster Pharmacyclics deal for ibrutinib FierceBiotech ... up with its third $50 million payday for the Btk inhibitor as the fifth patient with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma was signed up for a combo study that matches ibrutinib with bendamustine and rituximab. |
